

FOR IMMEDIATE RELEASE

Lee's Pharm Announced the Completion of Phase I Study for its first-in-class drug Declotana[®]

(Hong Kong, 18 April 2011) - Lee's Pharmaceutical Holdings Limited (Main Broad Stock: 0950; Website: www.leespharm.com), announced that it has successfully completed the Phase I study of its first-in-class anti-platelet drug Declotana[®]. The study was initiated in November, 2009 and during the ensuring 18 months, a total of 126 volunteers had been given the product intravenously with either single dose or multiple doses.

During the study, Declotana[®] had demonstrated predictable anti-platelet activity and exhibited excellent safety profile in healthy volunteers. It caused much less bleeding tendency compared to other class of anti-platelet drugs and has minimum impact on normal coagulation functions. In the maintenance dosing study, different desired levels of platelet inhibitions were achieved successfully that pave the way for the upcoming Phase II study. Further analysis of the results is ongoing and publication of the results will be made once the study report is ready.

Declotana[®] is an antagonist of platelet 1b receptors being developed to prevent thrombosis in patients undergone PTCA and stenting as well as for treatment of ischemic heart diseases such as unstable angina. The phase I study was to assess the safety and tolerability, as well as pharmacodynamic activity of Declotana[®]. To date, Declotana[®] appears safe and well tolerated and demonstrates expected pharmacodynamic activity.

"We are overwhelmed by the achievement of this important milestone for Declotana[®] development in China. As a first-in-class drug, Declotana[®] is the first platelet Ib antagonist to complete human phase I study. Its excellent safety profile and predicable anti-platelet activity demonstrated in the phase I study warrant further investigation. We schedule to start phase II study for acute coronary syndrome (ACS) in July, 2011" stated Dr. Benjamin Li, the Chief Executive Officer of the Group.

About Declotana[®]

Declotana[®] (递乐妥[®]), is a new molecular entity discovered and developed by the Group since 1995. It possesses the anti-platelet 1b receptors activity and is an effective anti-thrombosis agent in animal model. Platelet 1b receptors are critical to platelet adhesion to damaged endothelin of blood vessel which leads to the activation of platelet and subsequent thrombus formation. Animal studies have shown that intravenous injection of Declotana[®] effectively abolishes the cyclic flow reduction in canine model of unstable angina with much less



FOR IMMEDIATE RELEASE

prolongation of bleeding time than platelet 2b3a receptors antagonist. Animal studies have also shown that

Declotana[®] has a quite favorable safety profile compared with other platelet inhibitors. It is expected that Declotana[®] could have an important role in preventing thrombosis and plaque progression at sites of pathological endothelial injury, contributing to the treatment of unstable angina as well as to reduction of thrombosis in patients undergone PTCA and stenting. The Group has obtained patent in US and additional patent applications are underway.

About Lee's

Lee's Pharmaceutical Holdings Limited is a public biopharmaceutical company with over 16 years operation in China's pharmaceutical industry. It is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives and currently markets nine products. Leespharm focuses on several key therapeutic areas such as cardiovascular, oncology, dermatology and gynecology. It has more than 30 products under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from 18 US, European and Japanese companies. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life.

Safe Harbor Statement

The statements in this news release, other than the historical financial information, may contain forward-looking statements that involve risks and uncertainties that could cause actual results to differ from anticipated results. Further information on risk factor that could affect, among other things, Lee's financial condition and results of operations is detailed in Lee's IPO prospectus, as filed with the Main Board of the Stock Exchange of Hong Kong Limited.

For further information, please contact:

Vivian Fung

Tel: (852)2314-1282

Fax: (852)2314-1708

Email: info@leespharm.com